Comparing Incidence of Serious Adverse Events Between Laninamivir and Non-User of Neuraminidase Inhibitor in Influenza Patients

Trial Profile

Comparing Incidence of Serious Adverse Events Between Laninamivir and Non-User of Neuraminidase Inhibitor in Influenza Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Oct 2015

At a glance

  • Drugs Laninamivir (Primary) ; Antivirals
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 07 Oct 2015 New trial record
    • 26 Aug 2015 Results presented at the 31st International Conference on Pharmacoepidemiology and Therapeutic Risk Management.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top